Gastrointestinal Manifestations of COVID-19: A Review of What We Know

Abstract

Background: The coronavirus disease 2019 (COVID-19) is not just a disease of the respiratory system. The virus can affect the gastrointestinal (GI) tract as well. Recognizing the various manifestations in every organ system is important because these manifestations can contribute to community-based transmission. Methods: We outline the evidence of the pathophysiology of COVID-19 in the GI tract, the effects of the virus on the gut and liver, the presence of the virus in stool samples, and the potential for fecal-oral transmission of COVID-19. Most of the literature sources used in this paper are case studies from China following the surge of COVID-19 infection. Results: In patients with COVID-19, GI symptoms such as anorexia, nausea, vomiting, diarrhea, and abdominal pain have presented in conjunction with respiratory symptoms such as fever, shortness of breath, and cough. Evidence also shows acute hepatocellular injury, indicated by elevated liver enzymes such as alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase. Fecal-oral transmission of COVID-19 is suspected because of the presence of COVID-19 RNA in stool samples of COVID-19–positive patients. Conclusion: Even without the presence of respiratory symptoms, several GI symptoms are associated with COVID-19 infection, as well as possible fecal-oral transmission. Therefore, COVID-19 infection should be considered for patients presenting with primarily GI symptoms.

Zonulin, a marker of gut permeability, is associated with mortality in a cohort of hospitalised peruvian COVID-19 patients

“…Related to COVID-19 infection, SARS-CoV-2 affects the gastrointestinal tract as evidenced by gastrointestinal symptoms and detection of the virus in faeces ( Groff et al., 2021 ). Additionally, viral antigens have been found in intestinal enterocytes after resolution of clinical illness in adults ( Gaebler et al., 2021 ) and zonulin hyper permeability of the mucosal barrier coincides with SARS-CoV-2 antigenemia ( Yonker et al., 2021 ).…”

Covid-19, nervous system pathology, and Parkinson's disease: Bench to bedside

“…With both respiratory and gastrointestinal symptoms being quite common in the context of Covid-19 ( Cares-Marambio et al, 2021 ; Groff et al, 2021 ) and ACE2 being highly expressed in the alveolar epithelial type II cells and the intestinal endothelial cells ( Williams et al, 2021 ), some researchers have suggested the potential of SARS-CoV-2 entry through the intestine ( Lehmann et al, 2021 ; Mönkemüller, Fry, & Rickes, 2020 ; Zhang et al, 2020 ). RNA of the SARS-CoV-2 has been identified in stool samples and rectal swabs, even in cases with negative nasopharyngeal swabs ( Tang, Schmitz, Persing, & Stratton, 2020 ).…”

Increased TRIM31 gene expression is positively correlated with SARS-CoV-2 associated genes TMPRSS2 and TMPRSS4 in gastrointestinal cancers

“…Additionally, ACE2 receptors in the gastrointestinal tract play a crucial regulatory role in homeostasis, gut microbiome, and innate immunity. As a result, binding SARS-CoV-2 to these receptors and activating other epithelial surface proteins that can facilitate the entry of the virus may be one of the reasons for coronavirus infection in gastrointestinal tissues 35 . Conversely, live virus and RNA material that have been detected in the stools of COVID-19 patients were reported play a role in SARS-CoV-2 entry into cells starting from the apical surface and activating epithelial cell fusion in the intestine 36 – 38 .…”